Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells
Authors
Keywords
Ovarian cancer, c-Myc, 10058-F4, Therapeutics, Primary cell culture
Journal
Journal of Translational Medicine
Volume 12, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-08-20
DOI
10.1186/s12967-014-0226-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells
- (2013) H. Zirath et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- c-Myc and Cancer Metabolism
- (2012) D. M. Miller et al. CLINICAL CANCER RESEARCH
- Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts
- (2012) Christian Fabian et al. FEBS Journal
- Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells
- (2012) Chengwei He et al. Chinese Medicine
- In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues
- (2011) Caroline Haglund et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
- (2011) Y. Zhou et al. CANCER RESEARCH
- Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells
- (2011) Anna Priebe et al. GYNECOLOGIC ONCOLOGY
- Prognostic Impact of p53, p27, and C-MYC on Clinicopathological Features and Outcome in Early-Stage (FIGO I-II) Epithelial Ovarian Cancer
- (2011) Ingirídur Anna Skírnisdóttir et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53
- (2011) Joanna Zawacka-Pankau et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma
- (2011) Qiao-Lin Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity
- (2010) Jongchan Kim et al. BMC CANCER
- Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer
- (2010) M. Deraco et al. EJSO
- Molecular characterization of ovarian cancer by gene-expression profiling
- (2010) C. Gómez-Raposo et al. GYNECOLOGIC ONCOLOGY
- Pharmacogenomic Identification of c-Myc/Max-Regulated Genes Associated with Cytotoxicity of Artesunate towards Human Colon, Ovarian and Lung Cancer Cell Lines
- (2010) Serkan Sertel et al. MOLECULES
- Proepithelin Regulates Prostate Cancer Cell Biology by Promoting Cell Growth, Migration, and Anchorage-Independent Growth
- (2009) Giada Monami et al. AMERICAN JOURNAL OF PATHOLOGY
- Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer
- (2009) Won Deok Joo et al. Journal of Gynecologic Oncology
- Myc Prevents Apoptosis and Enhances Endoreduplication Induced by Paclitaxel
- (2009) Giuliana Gatti et al. PLoS One
- Reactive oxygen species and HIF-1 signalling in cancer
- (2008) Alex Galanis et al. CANCER LETTERS
- In Vivo/Ex Vivo and In Situ Assays Used in Cancer Research: A Brief Review
- (2008) Beverly A. Teicher TOXICOLOGIC PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search